Comprehensive Cancer Centers of Nevada | Las Vegas, NV
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.
Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Cohorts A and B
Cohort C
Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
No prior systemic therapy for LA/mUC
At least one measurable lesion by investigator assessment based on RECIST v1.1.
Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation
HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, on the provided tumor tissue sample
ECOG performance status of 0, 1, or 2
Cohort D
Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
Based on a participant's eligibility to receive treatment with standard of care therapies in Japan, participants must have received all of the following lines of therapy for LA/mUC:
At least one measurable lesion by investigator assessment based on RECIST v1.1.
ECOG performance status of 0 or 1
Cohort E
Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
No prior systemic therapy for LA/mUC
At least one measurable lesion by investigator assessment based on RECIST v1.1.
Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation
HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample
ECOG performance status of 0 or 1
Exclusion criteria
Cohorts A and B
Cohort C
Cohort D
Cohort E
There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.
Primary purpose
Allocation
Interventional model
Masking
332 participants in 7 patient groups
Loading...
Central trial contact
Seagen Trial Information Support
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal